Original research

The role of hyaluron acid in non-surgical treatment of Chronic Periodontitis – Systematic review

Vanessa Rocha Rodriguesa,*, Pedro Rochaa, Pedro Otãoa, Henrique Luisb, Susana Noronhac, Paulo Mascarenhasc

a Médico(a) Dentista, Aluno/a da especialização de Periodontologia e Implantes da Faculdade de Medicina Dentária de Lisboa, Lisboa, Portugal.  
b Higienista Oral, Coordenador do Departamento de Higiene Oral da Faculdade de Medicina Dentária da Universidade de Lisboa.  
c Médico(a) Dentista, Especialista em Periodontologia pela OMD, Professor(a) Auxiliar do Departamento de Periodontologia na FMDUL. Coordenador e Docente da Especialização em Periodontologia e Implantes na FMDUL.

A B S T R A C T

Objectives: The purpose of this review is to perform a systematic evaluation of the clinical effects of the local subgingival use of 0.8% or 0.2% hyaluronic acid (HA) as an adjunct to scaling and root planning in patients with chronic periodontitis.

Methods: An electronic search was performed on PubMed, Lilacs, and Cochrane, without any time or language restrictions, on May 9, 2018, using the following keywords: "hyaluronic acid"; "periodontitis"; "treatment of periodontitis"; and "scaling." The following parameters were evaluated: clinical attachment level (CAL) gain, probing depth (PD), bleeding on probing (BOP), plaque index (PI), and gingival index (IG). This review was registered with the identification number CRD42019131541 in the PROSPERO International Prospective Register of Systematic Reviews hosted by the National Institute for Health Research, University of York, Centre for Reviews and Dissemination.

Results: When applied to periodontitis, the combined treatment HA + SRP provides more satisfactory results than the conventional treatment of SRP alone in most of the outcome variables presented.

Conclusion: It can be concluded that hyaluronic acid is a chemical adjuvant to consider in periodontal therapy. (Rev Port Estomatol Med Dent Cir Maxilofac. 2020;61(2):57-63) © 2020 Sociedade Portuguesa de Estomatologia e Medicina Dentária. Published by SPEMD. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
**Resumo**

**Objetivos:** O objetivo desta revisão foi realizar uma análise sistemática que avalie os efeitos clínicos e microbiológicos do uso local subgengival de HA 0,8% ou 0,2% como adjuvante ao alisamento radicular em pacientes com periodontite crónica.

**Métodos:** Foi realizada uma pesquisa eletrônica nas seguintes bases de dados: PubMed, Lilacs e Chocrane sem restrições de tempo ou idioma, até 9 de Maio de 2018. Foram utilizadas as seguintes palavra-chave (“ácido hialurónico”; “periodontite”; “tratamento da periodontite”; “alisamento radicular”). Os seguintes parâmetros clínicos foram avaliados, nível de inserção clínica, profundidade de sondagem, hemorragia à sondagem, índice de placa e índice gengival. A revisão foi registrada com o número de identificação CRD42019131541, no PROSPERO International Prospective Register of Sistemmatic Reviews, hospedado pelo Instituto Nacional de Pesquisa em Saúde, Universidade de York, Centro de Revisões e Disseminação.

**Resultados:** A combinação da aplicação ácido hialurónico com o alisamento radicular, apresenta resultados clínicos mais satisfatórios, quando comparados com o alisamento radicular isolado.

**Conclusões:** Pode-se concluir que o ácido hialurónico é um adjuvante químico a considerar na terapia periodontal. (Rev Port Estomatol Med Dent Cir Maxilofac. 2020;61(2):57-63) © 2020 Sociedade Portuguesa de Estomatologia e Medicina Dentária. Published by SPEMD. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Material and methods

This review was registered with the identification number CRD42019131541 in the PROSPERO International Prospective Register of Systematic Reviews hosted by the National Institute for Health Research, University of York, Centre for Reviews and Dissemination.

An electronic search without time or language restrictions was undertaken between January and May 9, 2018, in the following databases: PubMed, Lilacs, and Cochrane, using the following keywords and Mesh terms: “hyaluronic acid”; “periodontitis; “treatment of periodontitis”; “scaling.”

In this systematic review, only randomized controlled clinical trials (RCTs) on the treatment of CP with SRP + HA were included. Either the test or control treatment group of each selected RCT was included in the article if the following inclusion criteria were met: healthy participants; moderate to severe CP with ≥ five sites of probing pocket depth (PPD) ≥ 5 mm; patients with at least 20 teeth; follow-up ≥ 12 weeks; human-based studies; HA applied during the non-surgical treatment of CP. Individuals were excluded if they had received periodontal treatment in the previous year and/or antibiotics 6 months before the study, were smokers, had chronic diseases (diabetes mellitus or rheumatoid arthritis), or were pregnant.

This systematic review applied the Preferred Reporting Items Systematic review and Meta-Analyses (PRISMA) statement and checklist, as well as the population, intervention, comparison, outcomes (PICO) method, as follows:

- P: Patients with CP
- I: SRP + HA
- C: Treatment of CP with either SRP + HA or SRP alone
- O: Clinical attachment level (CAL) gain, PPD, bleeding on probing (BOP), plaque index (PI), gingival index (GI), and relative attachment level (RAL)

The risk of bias analysis was performed with the Cochrane Collaboration Tool, by two authors (VR and PO). The risk of bias was classified as low when studies provided detailed information on all parameters analyzed. Studies that did not provide information on two or more parameters were considered as high-risk. Studies that provided information on only one of the parameters were classified as having a moderate risk of bias. All the included trials were described as randomized controlled trials, and all of the studies showed an unclear risk of the randomization method. Allocation in three of the included trials was classified as unclear because the method of allocation was not described. In two of the studies included allocation was classified as high-risk and in other two as low-risk. Blinding for participants was well conducted in three trials; the other trials did not have all the information required for this analysis, so they are classified as unclear and considered as having an unclear risk for blinding bias at outcome measuring. All of the included studies reported follow-up and whether the proposed outcomes were assessed, as described in the protocol. Subsequently, most studies, after the risk of bias assessment, were classified as having a high risk of bias.

Results

The study selection process is summarized in Figure 1. The search strategy resulted in seven papers. All data were extracted by two reviewers (VR and PO), independently and in duplicate, using data extraction forms.

All data collected were loaded to the Review Manager software and checked. The following information was recorded:

a. Publication status and year of publication.
b. Study design and duration of the follow-up.
c. Participants’ features: sample size, with at least 20 teeth, with ≥ five sites of PPD ≥ 5 mm.
d. Methodology of the trials: inclusion and exclusion criteria, randomization, conclusions, and clinical variables.
e. Characteristics of the interventions and control.
f. Source of funding and conflicts of interest.

After reading the title or abstract, 137 articles were excluded (inter-reader agreement k = 0.944±0.056; the following website was used for kappa calculation: https://www.graphpad.com/quickcalcs/kappa1.cfm). When the authors (VR and PO) disagreed in selecting an article for exclusion, judgment by a third author (PM) was solicited.

All authors of the included studies were contacted and asked if they had more information or unpublished material. Just one of the authors replied.

The full-text reports of the remaining ten articles led to the exclusion of three due to not meeting the inclusion criteria, as they included patients with PPD <4 mm, smokers, and also administered chlorhexidine in the test group.

The initial screening of titles and abstracts, in the Lilac database, resulted in two papers for full-text analysis. The two full-text reports were excluded due to not fitting the scope of this work. One of the articles’ was obtained by manual search.

All of the selected studies were randomized clinical trials with a 12-month follow-up. Four studies evaluated the application of 0.8% HA combined with SRP and three articles evaluated the application of 0.2% HA combined with SRP. Most studies suggested that a combined treatment composed of full-mouth SRP and topical administration of HA promoted periodontal healing in CP.

Shah et al. detected a significant reduction in PI and GI in both a HA group and a control group at 12 weeks (p<0.05). It also observed a significant reduction in PPD and an increase in RAL in both groups compared to baseline (p<0.05). Compared to the control, the HA group demonstrated a statistically significant reduction in PPD and an increase in RAL (p<0.05) at 12 weeks (Table 1). PI, GI, PPD, and CAL had also improved at 12 weeks (p<0.05) in both groups. Clinically, all indices except CAL had a more statistically significant reduction in tests than controls at 12 weeks. There were statistically significant differences between tests and controls at 12 weeks for GI. For PI, no significant differences were found between tests and controls at 12 weeks, with p-values >0.05 (Table 1). PPD at 12 weeks had lower significant levels in tests than controls, at p=0.4475 with 95% CI (0.0715, 0.8234). Regarding CAL, no significant differences were found between control and test sites for all time points.
Salavadi et al. observed statistically significant differences in all evaluated parameters between the test and control groups. At 12 weeks, the differences observed in the test and control groups were related to PI and BOP, which were significantly reduced in the test group. Regarding CAL and PPD, there were also more improvements in the test group than the control.

The results of another trial concluded that the application of 0.2 ml of a 0.8% HA subgingival gel for 1 week after root planning in the premolars and canines resulted in a significant reduction of BOP, PI, and PPD (Table 1). On the other hand, the three articles that evaluated the application of 0.2% HA combined with SRP indicated it improved the GI and BOP when compared with treatment with SRP alone (Table 2).

Rajan et al. showed that the use of HA as an adjunct to SRP benefited the periodontium health. All clinical parameters evaluated presented improvements compared to the control group. A greater reduction of BOP was observed in the test group. At 12 weeks, PPD showed a statistically significant reduction in the test group from 6.33±0.09 to 2.49±0.51, and in the control group from 6.09±1.26 to 4.36±1.29.

On the other hand, Xu et al. detected improvements in all clinical variables (p<0.05) in both groups, but with no clinical differences between tests and controls. It also found no differences between tests and controls in the tested microorganisms.

**Discussion**

The aim of this systematic review of the literature was to evaluate the clinical effects of 0.8% or 0.2% HA when used subgingivally as an adjunct to SRP in patients with CP.

HA is a natural component of our body and is abundant in the periodontal tissue; thus, it can be used in humans without
causing an immune or inflammatory response. It has viscoelastic properties, which allow it to act as a barrier against periodontal pathogens and make it easier to be used in the form of a gel, with easy application.\(^5\) Additionally, it has a pro-angiogenic, anti-inflammatory, and bacteriostatic role, which positively influences periodontal inflammation and healing when used alone or as an adjunct to periodontal mechanical therapy.\(^5\) Indeed, most of the studies exposed in this literature review confirm that the use of HA as an adjuvant to scaling seems to obtain better results in the treatment of periodontitis than scaling alone.\(^8\)-\(^11\),\(^13\)

**Table 1. Studies that assessed the application of 0.8% HA for chronic periodontitis treatment.**

<table>
<thead>
<tr>
<th>Author</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shah et al., 2017(^9)</td>
<td>PI: Test Group: 2.41% to 1.81%. Control Group: 2.33% to 1.82%. GI: Test Group: 2.36% to 1.74%. Control Group: 2.28% to 1.76%. PPD: Test Group: 5.37 mm to 2.37 mm. Control Group: 5.37 mm to 3.33 mm. RAL: Test Group: 9.17 mm to 6.70 mm. Control Group: 9.10 mm to 7.50 mm.</td>
</tr>
<tr>
<td>Salavadi et al., 2016(^1)</td>
<td>PI: Test Group: 2.28% to 0.60%. Control Group: 2.45% to 0.94%. PPD: Test Group: 7.33 mm to 4.5 mm. Control Group: 6.92 mm to 5.25 mm. BOP: Test Group: 95.64% to 28.45%. Control Group: 98.47% to 38.32%. CAL: Test group: 7.58 mm to 4.67 mm. Control Group: 7.67 mm to 6 mm.</td>
</tr>
<tr>
<td>Shammarri, et al., 2016(^1)</td>
<td>PPD: Test Group: 4.9 mm to 305 mm. Control Group: 4.85 mm to 3.5 mm. CAL: Test Group: 3.78 mm to 2.69 mm. Control Group: 3.94 mm to 2.69 mm. PI: Test Group: 26.38% to 23.14%. Control Group: 22.63% to 21.86%. BOP: Test Group: 24.48% to 16.45%. Control Group: 24.52% to 28.55%. GI: Test Group: 25.29% to 15.77%. Control Group: 23.71% to 29.23%.</td>
</tr>
<tr>
<td>Polepalle et al., 2015(^1)</td>
<td>BOP: Test Group: 1.00% to 0.22%. Control Group: 1.00% to 0.80%. PI: Test Group: 2.05% to 0.40%. Control Group: 2.15% to 1.90%. BOP: Test Group: 4.99 mm to 5.21 mm. Control Group: 2.45 mm to 4.49 mm. CAL: Test Group: 5.4 mm to 2.73 mm. Control Group: 5.41 mm to 4.71 mm.</td>
</tr>
</tbody>
</table>

PI – plaque index; GI – gingival index; BOP – bleeding on probing; PPD – probing depth; CAL – clinical attachment level; RAL – residual clinical attachment

**Table 2. Studies that assessed the application of 0.2% HA for chronic periodontitis treatment.**

<table>
<thead>
<tr>
<th>Author</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rajan et al., 2014(^1)</td>
<td>PPD: Test Group: 6.33 mm to 2.49 mm. Control Group: 6.09 mm to 4.36 mm. BOP: Test Group: 1.00% to 0.06%. Control Group 1.00% to 0.48%. CAL: Test Group: 10.18 mm to 6.91 mm. Control Group 9.12 mm to 7.48 mm.</td>
</tr>
<tr>
<td>Xu et al., 2004(^1)</td>
<td>PPD: Test Group: 5.3 mm to 4.3 mm. Control Group: 5.2 mm to 4.2 mm. Microbiological Parameters: Test Group Aa: 35% to 35%; Pg: 65% to 50%; Tf -85% to 70%. Control Group Aa: 35% to 30%; Pg: 65% to 60%; Tf: 90% to 70%. BOP: Test Group: 78% to 19%. Control Group: 72% to 23%. CAL: Test Group: 5.5 mm to 4.5 mm. Control Group: 5.4 mm to 4.71 mm.</td>
</tr>
<tr>
<td>Gontiya et al., 2012(^1)</td>
<td>PPD: Test Group: 6.57 mm to 4.82 mm. Control Group: 6.42 mm to 4.94 mm. GI: Test Group: 2.02% to 0.89%. Control Group: 2.04% to 1.19%. BOP: Test Group: 8.91 mm to 7.60 mm. Control Group: 8.56 mm to 7.64 mm.</td>
</tr>
</tbody>
</table>

GI – gingival index; BOP – bleeding on probing; PPD – probing depth; CAL – clinical attachment level; RAL – residual clinical attachment
Side effects of systemic antimicrobial therapy and possible poor compliance of the patient can be minimized by using locally applied antimicrobials. Therefore, a positive influence on the subgingival microbiota can be achieved with locally applied antimicrobials.8

Most of the studies showed a positive effect of HA application together with SRP on the clinical parameters evaluated.9-11,13 No adverse effects have been observed in its application. The use of HA in the non-surgical treatment of CP relies on its potential impact on the pathological onset, as well as its ability to improve wound healing, due to its previously demonstrated antimicrobial and anti-inflammatory properties,17,18 and its pro-angiogenic19,20 and osteoinductive potential.18,20

HA has been demonstrated to have a bacteriostatic action on periodontal pathogens when they are in the planktonic phase.17,18 However, HA has a lower bacteriostatic potential than chlorhexidine (CHX).18,22

All the included studies compared the outcomes between HA gel application after SRP and the application of a placebo after SRP. Rajan et al.13 detected clinical improvements in the HA group, such as a significant improvement in PPD and BOP and an improvement in CAL. Gontiya and Galgali17 showed a reduction of the gingival parameters in the HA group. It also analyzed the inflammatory infiltrate but did not found any significant differences between the two groups.2 Conversely, Polepalle et al.10 found a significant difference in the inflammatory infiltrate between the HA group and the placebo group. It also noticed a significant improvement in BOP and PPD in the HA group.10 On the other hand, Xu et al.11 did not find improvements in periodontal health following the use of HA as a complement to SRP (without any clinical or microbiological upgrading). However, in this study, the HA gel was applied only once a week for 6 weeks, which is not enough considering the recommended application regimen of three times per day for at least 4 to 8 weeks.

It is important to note that local application treatments are more effective because of their ability to provide localized high concentrations; however, they also have the disadvantage of gingival fluid clearance.23

The included studies do not provide full information on participants. Also, all studies had a follow-up of 12 months, which is relatively short, and, in some studies, the participants applied the products at home. Most studies of this systematic review, after the risk of bias assessment, were classified as having a high risk of bias, according to the Cochrane Collaboration guidelines.24

Conclusions

The data obtained from this systematic review suggest that HA can play a positive role in tissue repair and wound healing.

In periodontitis, the HA + SRP combined treatment offers more satisfactory results than the conventional treatment of SRP alone in most of the outcome variables presented. The findings suggest that the use of HA as an adjunct should be considered in periodontal therapy.

However, studies still need to be carried out to specify the methods of administration and establish proper recommendations in order to simplify its use.

Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that no patient data appear in this article.

Right to privacy and informed consent. The authors declare that no patient data appear in this article.

Conflict of interest

The authors have no conflicts of interest to declare.

REFERENCES